Exploring the Evolving Treatment Paradigm in the Management of Inflammatory Bowel Disease

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Gilead Sciences and Takeda Pharmaceuticals USA, Inc.

Description:
Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1.6 million people in the United States. This lifelong, systemic autoimmune illness often strikes patients at a young age and must be managed across a lifetime. According to the Crohn’s and Colitis Foundation of America, there are as many as 70,000 new cases diagnosed in a year. Within IBD, there are two types that fall under its umbrella – Crohn’s disease and Ulcerative colitis. Ulcerative colitis causes inflammation and sores in the innermost lining of your large intestine and rectum. Crohn’s disease causes inflammation of your digestive tract which can cause abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.

The treatment goal for IBD is to reduce the inflammation, in hopes of achieving reduced symptoms and possibly remission. Immediate goals are to control the symptoms, induction of remission, and to help improve a patient’s quality of life, while long-term goals include maintenance of a corticosteroid-free clinical remission, mucosal healing, endoscopic remission, prevention or cure of complications, restoration, and maintenance of proper nutrition. The first step for IBD treatment is aminosalicylates, which are useful for treating flares of IBD and for maintaining remission. Antibiotics can also be used to treat bacterial infections that may result from abscesses or fistulas. Corticosteroids are rapid-acting anti-inflammatory agents and are indicated for acute flares of disease only. They have no role in the maintenance of remission. Immunomodulators have a slower onset of action and work to reduce patients’ overactive immune system but unlike corticosteroids, they can be used as a long-term treatment. And the fifth way to treat the disease is with biologics, which are proteins that stop certain molecules in the body from causing inflammation in the GI tract. These are usually prescribed to those living with moderate to severe cases of IBD who haven’t responded to other types of treatment.

There is now an understanding of the pathogenesis of IBD and the development of appropriate management that is helping to target the inflammatory pathways which is now considered a high priority. An increasing number of clinical trial options have shown favorable short- and long-term outcomes, and as clinicians continue to find the right strategy to treat IBD, new and emerging treatment strategies may offer additional therapeutic options to address the unmet needs of these patients. Clinicians have recently been equipped with more treatment options, including janus kinase (JAK) inhibitors. Several others have just completed late stage clinical trials and are currently undergoing regulatory review. These new options have shown improved efficacy and safety in IBD, and healthcare professionals must be educated on these agents and the potential risks that come along with any treatment option.

Upon completion of this activity, participants will be able to:

  • Analyze the safety, efficacy and mechanisms of action for current and emerging treatments of inflammatory bowel disease (IBD), including those with specific therapeutic targets

  • Discuss the importance of early diagnosis and how that can have an impact on successful IBD management

  • Identify strategies for patients who would benefit from biologic agents, including effective treat-to-target strategies

  • Explore the role of non-biologic pharmacologics in the management of IBD

  • Evaluate the use of a collaborative care team to overcome different challenges in IBD management

  • Assess different individualized treatment plans for patients who fail to achieve remission
     

Faculty: Francis Farraye, MD, MSc
Senior Associate Consultant
Section of Gastroenterology and Hepatology
Mayo Clinic, Jacksonville, FL

Disclosure:

Dr. Farraye serves on an advisory board for Ferring, Janssen, Merck, Pfizer, and Takeda. He serves as a consultant for Braintree Labs. He serves on the data safety monitoring board for Lilly and Protagonist. He has self-managed stock in Innovation Pharma. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Gilead Sciences and Takeda Pharmaceuticals USA, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue